To continue the discussion about the novel therapies in the form of questions and answers, join us on Monday, 25th May 2020 at 19:00 Brussels time. We will look at the prospects of gene therapy for people with haemophilia and inhibitors, who have been so far excluded from the target group for gene therapy.
The conversation will be set in the framework of the patient perspective and will look at what people with inhibitors can expect in terms of gene therapy, as well as what questions need to be asked if and when this option becomes real for this patient cohort.
Our guest will be the EHC President Declan Noone, who is actively involved in the work on the EHC Novel Product Newsletter. The newsletter covers recent major developments and is divided by different types of disorders for which there is an update to report. The information provided in this newsletter is compiled from multiple sources, including presentations at recent scientific meetings, websites, financial information and by writing directly to pharmaceutical companies. It is then redrafted and presented in easy-to-understand language. This newsletter is updated periodically.